The standard serological tests included in the classification criteria[@annrheumdis-2014-206483_R1] for antiphospholipid syndrome (APS) are those to detect immunoglobulin G (IgG) and IgM antibodies to cardiolipin (aCL) or β-2-glycoprotein I (anti-β2GPI) and the lupus anticoagulant. It is increasingly recognised, however, that some patients have typical thrombotic and non-thrombotic features of APS but test repeatedly negative in these routinely used assays. It has been suggested that these patients have the so-called seronegative APS (SN-APS).[@annrheumdis-2014-206483_R2] In a retrospective study, there were no significant differences in clinical manifestations between 87 patients with seropositive APS and 67 with SN-APS.[@annrheumdis-2014-206483_R3] Several authors have suggested that in these 'seronegative' patients, clinically relevant antibodies can be detected by looking for different isotypes, particularly IgA[@annrheumdis-2014-206483_R2] and/or different antigen specificity[@annrheumdis-2014-206483_R4] or by using different techniques[@annrheumdis-2014-206483_R4] [@annrheumdis-2014-206483_R5] than those of the routine assays. In a recent paper, 79% of 24 patients with SN-APS had serum antibodies detectable by such strategies.[@annrheumdis-2014-206483_R5] There is considerable evidence that IgA antiphospholipid antibody tests may be a useful diagnostic tool in APS.[@annrheumdis-2014-206483_R6] Antibodies to domain I (DI) of β2GPI have attracted particular interest as they are strongly associated with thrombosis.[@annrheumdis-2014-206483_R7] No formal analysis of anti-DI antibodies (of any isotype) or IgA antiphospholipid antibodies in patients with SN-APS has been reported.

Serum samples from 80 patients with APS (40 with seropositive APS fulfilling classification criteria[@annrheumdis-2014-206483_R1] and 40 with SN-APS fulfilling clinical but not serological criteria) from St Thomas' Hospital (STH) and 200 healthy controls were tested at University College London (UCL) in nine ELISAs---IgG, IgM and IgA for each of aCL, anti-β2GPI and anti-DI. ELISAs were carried out blind to the clinical and serological information from STH using methods published previously[@annrheumdis-2014-206483_R10] with appropriate modifications to detect IgA. We defined the cut-off for a positive result in each assay as the 99th centile of the healthy population.

Clinical features of the patients are shown in [table 1](#ANNRHEUMDIS2014206483TB1){ref-type="table"} and results of the ELISAs in [table 2](#ANNRHEUMDIS2014206483TB2){ref-type="table"}. For ease of interpretation, [table 2](#ANNRHEUMDIS2014206483TB2){ref-type="table"} groups the four criteria tests used in routine clinical practice (IgG aCL, IgM aCL, IgG anti-β2GPI and IgM anti-β2GPI) together at the top and the non-standard ELISAs (all anti-DI, IgA aCL and IgA anti-β2GPI) below. In the seropositive APS group, we found large numbers of samples that tested positive in the five non-criteria ELISAs. Thus 62.5% were positive in at least one of these assays. In the SN-APS group, we found no samples positive in the standard assays (thus 100% agreement with STH in tests at UCL done blind to STH results) but four (10%) were positive in one of the non-standard ELISAs.

###### 

Clinical features of patients in the study

                        APS group   SN-APS group
  --------------------- ----------- --------------
  Number in study       40          40
  Gender                            
   Male                 4           0
   Female               36          40
   Mean age at sample   45.3        46.1
  Diagnosis                         
   PAPS                 22          N/A
   SLE/APS              18          N/A
   SN-PAPS              N/A         35
   SN-APS/SLE           N/A         5
  Thrombosis            34          25
   Venous               19          12
   Arterial             15          13
   None                 6           15
  Pregnancies?                      
   Yes                  33          39
   No                   3           1
   N/A                  4           0
  Pregnancy morbidity   23          35
   Miscarriage          12          29
   Stillbirth           19          25
   Prematurity          4           7
   Preeclampsia         7           10
   None                 17          5
  LA positivity                     
   Yes                  27          0
   No                   13          40

LA, lupus anticoagulant; PAPS, Primary Antiphospholipid Syndrome; SLE, systemic lupus erythematosus; SN-APS, seronegative antiphospholipid syndrome.

###### 

ELISA results

                                                 Seropositive APS (n=40)   SN-APS (n=40)
  ---------------------------------------------- ------------------------- ---------------
  Standard ELISAs                                                          
   No. (%) testing positive for IgG anti-CL      18 (45%)                  0
   No. (%) testing positive for IgG anti-β2GPI   6 (15%)                   0
   No. (%) testing positive for IgM anti-CL      4 (10%)                   0
   No. (%) testing positive for IgM anti-β2GPI   9 (22.5%)                 0
  Anti-DI ELISAs                                                           
   No. (%) testing positive for IgG anti-DI      11 (27.5%)                3 (7.5%)\*
   No. (%) testing positive for IgM anti-DI      9 (22.5%)                 0
   No. (%) testing positive for IgA anti-DI      7 (17.5%)                 0
  Other IgA ELISAs                                                         
   No. (%) testing positive for IgA anti-CL      12 (30%)                  0
   No. (%) testing positive for IgA anti-β2GPI   8 (20%)                   1 (2.5%)\*

The cut-off for positive in each assay was defined as 99th centile of the healthy control population.

\*The titres of IgG anti-DI in the three positive patients were 16 absorbance units (AU), 15.3 AU and 22.2 AU respectively compared with the positive cut-off of 10 AU. The titre of IgA anti-β2GPI in the one positive patient was 16 AU compared with a positive cut-off of 9 AU.

anti-β2GPI, anti-β-2-glycoprotein; CL, cardiolipin; DI, domain I; Ig, immunoglobulin; SN-APS, seronegative antiphospholipid syndrome.

In conclusion, this blinded serological analysis of seropositive and SN-APS cohorts confirms that anti-DI, IgA aCL or IgA anti-β2GPI antibodies, while present in a significant proportion of seropositive patients with APS, may also pick up a small proportion of patients with SN-APS. In this study, the IgG anti-DI assay had the highest pick-up rate (despite samples testing negative for anti-β2GPI), which is interesting given the accumulating evidence that IgG anti-DI antibodies are important in the pathogenesis of APS.[@annrheumdis-2014-206483_R7]
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